Trial Profile

Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device (DOSED)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OPC 1 (Primary)
Indications Spinal cord injuries
Focus Adverse reactions
Acronyms DOSED
Sponsors Lineage Cell Therapeutics

Most Recent Events

18 Jun 2025 Last checked against ClinicalTrials.gov: US National Institutes of Health.
12 Jun 2025 Planned End Date changed from 27 Apr 2037 to 30 Jun 2037.
12 Jun 2025 Planned primary completion date changed from 10 Jun 2027 to 10 Aug 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com